Medical Oncologist
Drug resistance and next-line options
When Sunitinib Stops Working: — Resistance and What Comes Next
Sunitinib can stop controlling cancer over time, and this is an expected part of how targeted therapies work — not a sign that you or your treatment team have done something wrong. Several second-line options exist, and which one fits depends on your cancer type.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Resistance is expected — Tumour cells adapt over time. This is a recognised pattern with most targeted therapies, not a treatment failure.
- The mechanism can vary — Cancer cells evade sunitinib in different ways, which is why the next-best option is not the same for everyone.
- Multiple options exist — NCCN and ESMO guidelines name several approved second-line treatments for the cancers sunitinib is used in.
- Your cancer type decides the path — The options for kidney cancer, GIST, and pancreatic neuroendocrine tumours differ — your oncologist will match the choice to your diagnosis.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Sunitinib stops working when cancer cells find new ways around the pathway it blocks. This is called acquired resistance. When it happens, your oncologist will consider switching to a drug from a different class — an mTOR inhibitor, a different tyrosine kinase inhibitor, or an immunotherapy — depending on your cancer type and overall fitness.
What do these terms mean?
- Acquired resistance
- The cancer responds to sunitinib at first, then stops. Tumour cells change over time and find new ways to survive despite the drug. This is the most common pattern with targeted therapy.
- Primary resistance
- The tumour does not respond to sunitinib from the start. Scans show no shrinkage or stabilisation even on the first course of treatment.
- TKI (tyrosine kinase inhibitor)
- The drug class sunitinib belongs to. TKIs block chemical signals that tell cancer cells to divide and form new blood vessels. Different TKIs target overlapping but not identical pathways — resistance to one does not always mean resistance to all of them.
- VEGF pathway
- The main signalling route sunitinib targets. Tumours use this pathway to grow new blood vessels. Resistance often means the tumour has switched to a different route for the same purpose.
- mTOR inhibitor
- A drug class that targets a separate signalling pathway inside the cancer cell. It is one of the standard options your oncologist may consider after sunitinib stops working.
- Second-line treatment
- Any treatment given after the first one stops working. It does not mean the second treatment is less effective — in several cancers, second-line options have well-established roles in international guidelines.
What should you do when sunitinib stops working?
- Tell your team about any new or returning symptoms — do not wait for your next scheduled appointment
- Ask your oncologist which second-line option is most appropriate for your specific cancer type
- Find out when your next response-assessment scan is and what it will be looking for
- Ask whether a repeat biopsy is worth doing to check for new changes in the tumour
- Ask whether any clinical trials are open for your situation
- Ask for a referral to a specialist centre if your cancer type is uncommon
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
Why does sunitinib stop working over time?
Sunitinib blocks a specific set of chemical signals that tumours use to grow new blood vessels. Without that blood supply, a tumour cannot grow quickly.
Over time, some tumour cells develop changes that let them use alternative pathways to get the same blood supply — bypassing the route sunitinib blocks. Researchers attribute this to several mechanisms, including the activation of other growth factor pathways and changes in how the tumour interacts with its surrounding tissue.
A separate pattern, primary resistance, means the tumour never responded because those alternative pathways were already active before treatment started.
No single mechanism explains every case. This is one reason why the most appropriate next treatment is not the same for all patients.
What are the second-line options after sunitinib?
The options depend on your cancer type. Sunitinib is used in renal cell carcinoma, gastrointestinal stromal tumours, and pancreatic neuroendocrine tumours, and the second-line landscape is different for each.
For renal cell carcinoma, NCCN and ESMO guidelines list several options after sunitinib progression, including cabozantinib, nivolumab, axitinib, and combinations such as lenvatinib with everolimus. Your oncologist will weigh your fitness, the pace of progression, and how you responded to sunitinib when choosing between them.
For gastrointestinal stromal tumours progressing after sunitinib, guideline-supported options include regorafenib and ripretinib. For pancreatic neuroendocrine tumours, everolimus and other agents may be considered.
The choice is not automatic. Your oncologist will assess how you are feeling and how quickly the cancer is moving. Some patients are well enough to consider combination regimens; others are better served by a single agent that is easier to tolerate.
Did you know?
Resistance to sunitinib does not necessarily mean resistance to all drugs in its class. A proportion of patients with renal cell carcinoma respond to a different TKI after sunitinib progression — a pattern recognised in both NCCN and ESMO guidance and reflected in the approved second-line options.
The reason is that different TKIs block overlapping but not identical targets. Switching to one with a different profile can still achieve tumour control in a proportion of patients.
Source: NCCN Guidelines for Kidney Cancer; ESMO Clinical Practice Guidelines for Renal Cell Carcinoma
Explore 75 more Kidney, Ovarian & Sarcoma Targeted Medicines topics
Drug Deep Dive: Sunitinib (Sutent)
- Diet and Nutrition While on Sunitinib
- Drug, Food and Supplement Interactions With Sunitinib
- Fertility, Pregnancy and Contraception on Sunitinib
- Hand-Foot Skin Reaction on Sunitinib: Prevention From Day One
- How Does Sunitinib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Sunitinib Take to Work?
- How Long Will You Stay on Sunitinib?
- Mouth Sores, Taste Loss and Yellow Skin Discolouration on Sunitinib
- Sunitinib (Sutent, Sunitix): The Complete Patient Guide
- Sunitinib After Kidney Surgery and for GIST: Two Different Settings
- Sunitinib Myths: Hair Colour Change, Dose Cuts and 'Weaker Treatment'
- Sunitinib Price in India: Brand, Generic and Monthly Cost
- Sunitinib Side Effects: The Complete List and Timeline
- Sunitinib Success Rate and Survival: An Honest Look at the Numbers
- Sunitinib and Immunotherapy: Where Combinations Fit in Kidney Cancer
- Sunitinib in Elderly Patients and Those With Other Illnesses
- Sunitinib vs Pazopanib vs Cabozantinib for Kidney Cancer
- Taking Sunitinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Sunitinib
- The 4-Weeks-On, 2-Weeks-Off Sunitinib Schedule and the 2/1 Alternative
- Thyroid Failure and Fatigue on Sunitinib: The Test to Repeat Every Cycle
- When Sunitinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Sunitinib? Kidney Cancer, GIST and Pancreatic Neuroendocrine Tumours
- Will Insurance or a Government Scheme Pay for Sunitinib?
- Work, Travel and Daily Life on Sunitinib
Drug Deep Dive: Olaparib (Lynparza)
- Adjuvant Olaparib After Early Breast Cancer Surgery
- Anaemia and Extreme Fatigue on Olaparib
- Blood Cancer Risk After Long-Term Olaparib: How Real Is It?
- Diet and Nutrition While on Olaparib
- Drug, Food and Supplement Interactions With Olaparib
- Fertility, Pregnancy and Contraception on Olaparib
- How Does Olaparib Work? The PARP Inhibitor Explained
- How Long Does Olaparib Take to Work?
- How Long Will You Stay on Olaparib?
- Maintenance Olaparib: Taking a Drug When There Is No Visible Cancer
- Nausea on Olaparib: Managing the Most Common Side Effect
- Olaparib (Lynparza, Olanib): The Complete Patient Guide
- Olaparib Myths: 'Only for BRCA', 'It's Chemo', 'It Causes Cancer'
- Olaparib Price in India: Brand, Generic and Monthly Cost
- Olaparib Side Effects: The Complete List and Timeline
- Olaparib Success Rate and Survival: An Honest Look at the Numbers
- Olaparib With Bevacizumab or Hormone Therapy: Combination Regimens
- Olaparib in Elderly Patients and Those With Other Illnesses
- Olaparib vs Niraparib vs Talazoparib: Comparing PARP Inhibitors
- Taking Olaparib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Olaparib
- When Olaparib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Olaparib? BRCA-Mutated Ovarian, Breast, Prostate and Pancreatic Cancer
- Will Insurance or a Government Scheme Pay for Olaparib?
- Work, Travel and Daily Life on Olaparib
Drug Deep Dive: Pazopanib (Votrient)
- Diarrhoea and Blood Pressure Rise on Pazopanib
- Diet and Nutrition While on Pazopanib
- Drug, Food and Supplement Interactions With Pazopanib
- Fertility, Pregnancy and Contraception on Pazopanib
- Hair Turning White and Skin Lightening on Pazopanib
- How Does Pazopanib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Pazopanib Take to Work?
- How Long Will You Stay on Pazopanib?
- Liver Toxicity on Pazopanib: Why LFTs Are Checked Every Two Weeks
- Pazopanib (Votrient, Pazonib): The Complete Patient Guide
- Pazopanib Combinations: Why It Is Usually Given Alone
- Pazopanib Myths: Hair Colour, Liver Damage and Stopping Early
- Pazopanib Price in India: Brand, Generic and Monthly Cost
- Pazopanib Side Effects: The Complete List and Timeline
- Pazopanib Success Rate and Survival: An Honest Look at the Numbers
- Pazopanib for Soft Tissue Sarcoma: What It Can and Cannot Do
- Pazopanib in Elderly Patients and Those With Other Illnesses
- Pazopanib in Kidney Cancer vs Sarcoma: Two Different Treatment Goals
- Pazopanib vs Sunitinib: Comparing Toxicity and Quality of Life
- Taking Pazopanib on an Empty Stomach: Why the Timing Rule Exists
- Tests and Monitoring While You Are on Pazopanib
- When Pazopanib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Pazopanib? Kidney Cancer and Soft Tissue Sarcoma
- Will Insurance or a Government Scheme Pay for Pazopanib?
- Work, Travel and Daily Life on Pazopanib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Does sunitinib stopping mean I am running out of options?
No. Resistance to sunitinib is expected with long-term use, and the second-line landscape for the cancers it is used in is well-developed. For renal cell carcinoma in particular, NCCN and ESMO guidelines list multiple approved options after progression. Being on your second treatment does not mean you are near the end of what can be offered — it means you are moving to the next step in a planned sequence.
How will my doctor know sunitinib has stopped working before I feel worse?
Response-assessment scans — usually CT, sometimes PET-CT — are the main way your team tracks whether treatment is still controlling the cancer. Progression is often visible on imaging before symptoms change noticeably. This is why attending your scheduled scan dates matters, and why you should tell your team about any new symptoms between scans rather than waiting for your next appointment.
Can I go back on sunitinib after trying something else?
In some situations, yes. Rechallenge with sunitinib after a treatment break or after a different second-line agent is something oncologists consider in certain patients, particularly in renal cell carcinoma. Whether it is appropriate depends on why sunitinib was stopped, how well you responded to it, and how you tolerated it. Ask your oncologist directly whether this is a realistic option for your situation.
Will resistance to sunitinib mean other similar drugs will not work either?
Not necessarily. Different TKIs target overlapping but not identical pathways, and a proportion of patients do respond to a second TKI after sunitinib. This is reflected in the approved second-line options listed in NCCN and ESMO guidance. The degree of cross-resistance depends on the specific mechanism that drove resistance in your tumour — something that cannot always be determined without a repeat biopsy, and not always even then.
How quickly does resistance to sunitinib usually develop?
The timing varies between patients and cannot be predicted for any individual. Your oncologist monitors response through regular scans, and the schedule is designed to catch progression before it becomes symptomatic where possible. If you feel the gaps between your scans are longer than you are comfortable with, that is a reasonable thing to raise at your next appointment.
Is there anything I can do to slow resistance?
There is no proven personal action that delays resistance to sunitinib. Taking the drug as prescribed — at the dose and schedule your team recommends — gives it the best chance of working for as long as it can. Dose reductions taken without medical guidance can reduce its effectiveness. Reporting side effects promptly helps your team make adjustments that keep you on treatment, rather than stopping it earlier than necessary.